Preferred Label : Lorpucitinib;
NCIt definition : An orally bioavailable pan-inhibitor of the Janus associated-kinases (JAKs), with
potential immunomodulatory and anti-inflammatory activities. Upon oral administration,
lorpucitinib works in the gastrointestinal (GI) tract where it targets, binds to and
inhibits the activity of the JAKs, thereby disrupting JAK-signal transducer and activator
of transcription (STAT) signaling pathways and the phosphorylation of STAT proteins.
This may inhibit the release of pro-inflammatory cytokines and chemokines, reducing
inflammatory responses and preventing inflammation-induced damage. The Janus kinase
family of non-receptor tyrosine kinases, which includes tyrosine-protein kinase JAK1
(Janus kinase 1; JAK1), tyrosine-protein kinase JAK2 (Janus kinase 2; JAK2), tyrosine-protein
kinase JAK3 (Janus kinase 3; JAK3) and non-receptor tyrosine-protein kinase TYK2 (tyrosine
kinase 2), plays a key role in cytokine signaling and inflammaton.;
UNII : OE1QTY7C25;
InChIKey : NJKMSBSVJSQUBU-SHTZXODSSA-N;
CAS number : 2230282-02-5; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 2230282-02-5
alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo
G-SRS /a ;
Molecule name : JNJ 64251330; JNJ-64251330;
NCI Metathesaurus CUI : CL1412056;
Origin ID : C174797;
UMLS CUI : C5420960;
Semantic type(s)
- concept_is_in_subset
- has_target
